

Nikolai Kunicher is the CEO of NeuroTrigger Located in Tel Aviv. NeuroTrigger developed the wearable artificial blinking system for patients with facial paralysis. Lack of blinking due to facial paralysis causing many painful side effects and even can cause loss of vision. Use of our system, eliminates those side effects, allowing patients to regain to full function. In addition to the support of the IIA, the company successfully raised her seed round and now in preparation of the FDA submission file.

Nikolai has been leading projects and leading companies in the health-tech sector for the past 12 years including companies like Betalin Therapeutics, Hadassah Medical Center and AVA Biodefender. During the work in the industry, Nikolai gained experience in IP, Fund Raising, Clinical and Regulatory planning, Business development and many other areas. During his work, Nikolai created multinational collaboration that led to receiving of millions in EU funding, opened subsidiary companies abroad and brought a lot of new value to the companies.

Previous to his industry experience, Nikolai received his PhD in Microbiology from the Hebrew University and his MBA from Netanya Academic College. He is an author of scientific papers and few patent applications.